Birtley, James R.
Alomary, Mohammad
Zanini, Elisa
Antony, Jane http://orcid.org/0000-0002-2424-5470
Maben, Zachary
Weaver, Grant C. http://orcid.org/0000-0003-1151-2944
Von Arx, Claudia
Mura, Manuela
Marinho, Aline T.
Lu, Haonan http://orcid.org/0000-0002-2472-7488
Morecroft, Eloise V. N.
Karali, Evdoxia
Chayen, Naomi E. http://orcid.org/0000-0003-2861-2458
Tate, Edward W. http://orcid.org/0000-0003-2213-5814
Jurewicz, Mollie
Stern, Lawrence J. http://orcid.org/0000-0001-9870-8557
Recchi, Chiara http://orcid.org/0000-0003-1605-0945
Gabra, Hani http://orcid.org/0000-0002-3322-4399
Article History
Received: 8 March 2018
Accepted: 6 June 2019
First Online: 17 July 2019
Competing interests
: H.G. is a VP head of Oncology Clinical Discovery at AstraZeneca (Concurrent with his position as Imperial College London tenured chair in medical oncology) and has ownership interest (including patents) in Patent to develop OPCML-based therapeutics. The remaining authors declare no competing interests.